CJC-1295 – With DAC (10mg)

What is CJC-1295 – With DAC (10 mg)?

CJC-1295 – With DAC (Drug Affinity Complex) is a synthetic research peptide classified under Muscle Growth & Performance Peptides. In laboratory and preclinical settings, it is used to study growth hormone–related signaling pathways and broader endocrine communication under controlled experimental conditions. Researchers utilize this peptide to examine how specific signaling fragments interact with cellular systems involved in hormone regulation and physiological adaptation.

CJC-1295 is derived from a modified fragment of growth hormone–releasing hormone (GHRH). The addition of the Drug Affinity Complex (DAC) is intended to increase peptide stability and prolong its persistence in experimental models. This structural modification allows investigators to explore sustained receptor engagement and extended signaling activity, making it particularly useful for research designs that require observation over longer timeframes rather than short-acting responses.

Product Specifications

• Category: Peptides
• Subcategory: Muscle Growth & Performance Peptides
• CAS Number: 863288-34-0
• Peptide Sequence:
  Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Malimide-beta-Ala)-NH2
• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight:4 g/mol
• Purity: ≥ 95% (verified using standard analytical methods)
• Packaging Format: Lyophilized powder, 10 mg vial
• Storage Conditions: Store at 2–8 °C (≤ –20 °C for long-term storage). Protect from light.
• Intended Use: For laboratory research use only

Key Characteristics of CJC-1295 – With DAC (10 mg)

• Defined GHRH-analog peptide: Used as a controlled research tool in GH-axis signaling studies.
• “With DAC” modification: The inclusion of the Drug Affinity Complex (DAC) prolongs peptide stability and supports longer receptor engagement in experimental designs.
• High purity (≥95%): Intended to reduce confounding from impurities in analytical and cell-based workflows.
• Research-only positioning: Used in non-clinical laboratory settings for mechanistic and measurement-focused studies.
• Cold storage + light protection required: Basic handling expectations to help preserve peptide integrity prior to experimental use.
• Frequently used in cell-based and preclinical model systems to study GHRH receptor activation, downstream signaling cascades, and GH-axis biomarker responses under defined conditions.

How CJC-1295 – With DAC (10 mg) Supports Research

CJC-1295 – With DAC is commonly used to examine GHRH receptor–linked signaling and downstream GH-axis biomarkers in controlled models. Because it is referenced as a GHRH analog in analytical and preclinical literature, it can serve as a test article for labs evaluating pathway responses over time, comparing peptide analogs, or validating detection and characterization methods for GHRH-related compounds.

The DAC modification distinguishes this version from non-DAC variants by allowing longer observation windows in experimental designs. Its role in research is exploratory and focused on mechanistic understanding rather than on therapeutic or clinical outcomes.

Research Applications & Usage Information

CJC-1295 – With DAC (10 mg) is commonly referenced in research contexts such as:

• Endocrine signaling studies: Used in research programs examining GHRH‑linked signaling and GH-axis pathway behavior in controlled in‑vitro and preclinical systems.
• Time-course experiments: “With DAC” versions are often selected for designs where researchers want clearer timing separation between exposures and readouts.
• Comparative peptide research: Included in side-by-side studies comparing GHRH analogs or related peptides for assay response differences (model-dependent).
• Analytical method development: Used in workflows that require characterization of GHRH analogs (e.g., mass-spectrometry–based identification approaches).
• Biomarker-focused assays: Incorporated into experiments tracking GH-axis–associated markers under controlled conditions (endpoint-dependent).

Handling and Storage Recommendations

• Store at 2–8 °C and protect from light when not in use.
• Keep the container tightly sealed to reduce exposure to moisture and ambient contaminants.
• Minimize temperature cycling (repeated warm/cool changes) to help reduce degradation risk.
• Use standard laboratory PPE and follow your facility’s SOPs for peptide reagents.
• Dispose of materials properly in accordance with institutional and local regulatory requirements.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
2. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. doi:10.1016/j.ghir.2009.03.001
3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
4. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536